Royal Bank of Canada
BIS icon

Royal Bank of Canada’s ProShares UltraShort NASDAQ Biotechnology BIS Stock Holding History

Royal Bank of Canada’s Portfolio BIS Stock Details BIS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q3 		– Sell
-25
Closed -$8K – 6392
2016
Q2 		$8K Buy
+25
New +$7.9K ﹤0.01% 5806

Other funds holding BIS

Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
BPC
Banque Pictet & Cie Geneva 73, Switzerland $16B AUM 29.1% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return
USGIU
U.S. Global Investors (USGI) San Antonio, Texas $1.04B AUM 73.31% 1-Year Est. Return
Toronto Dominion Bank
Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $69.7B AUM 40.86% 1-Year Est. Return
CG
Cutler Group San Francisco, California $307M AUM 45.11% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
FTUS
Flow Traders U.S. New York $3.16B AUM 19.52% 1-Year Est. Return
HR
Howe & Rusling Rochester, New York $1.53B AUM 21.45% 1-Year Est. Return

Royal Bank of Canada's BIS Position: Q3 2016 in Review

Royal Bank of Canada sold out of ProShares UltraShort NASDAQ Biotechnology (BIS) in Q3 2016, closing a stake of 25 shares — an estimated $8K sold.

Royal Bank of Canada first reported a position in BIS in Q2 2016 and held it in 1 quarter. The position peaked at $8K in Q2 2016. 10 funds tracked by Wall St. Rank hold BIS as of Q3 2016.

  • Royal Bank of Canada reported no remaining ProShares UltraShort NASDAQ Biotechnology position as of Q3 2016 after selling out during the quarter.
  • Royal Bank of Canada sold 25 ProShares UltraShort NASDAQ Biotechnology shares in Q3 2016, an estimated $8K.
  • Royal Bank of Canada first reported a position in ProShares UltraShort NASDAQ Biotechnology in Q2 2016 and held it in 1 quarter.
  • Royal Bank of Canada's ProShares UltraShort NASDAQ Biotechnology position peaked at $8K in Q2 2016.
  • 10 funds tracked by Wall St. Rank held ProShares UltraShort NASDAQ Biotechnology as of Q3 2016.

Based on Royal Bank of Canada's 13F filing for Q3 2016, filed 14 Nov 2016.